Cargando…

TIGIT in Lung Cancer: Potential Theranostic Implications

TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on various immune cells, including T cells, NK cells, and dendritic cells. TIGIT interacts with different ligands, such as CD155 and CD112, which are highly expressed on cancer cells, leading to the suppress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pescia, Carlo, Pini, Giuditta, Olmeda, Edoardo, Ferrero, Stefano, Lopez, Gianluca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145071/ https://www.ncbi.nlm.nih.gov/pubmed/37109579 http://dx.doi.org/10.3390/life13041050

Ejemplares similares

A Rare Case of Urinary Bladder Hamartoma Clinically Mimicking an Urothelial Carcinoma: A Case Report and Review of the Literature
por: Pescia, Carlo, et al.
Publicado: (2023)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023)

Thymic Epithelial Tumors: An Evolving Field
por: Kuhn, Elisabetta, et al.
Publicado: (2023)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
por: Rotte, Anand, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies
por: Hasan, Md Faqrul, et al.
Publicado: (2023)

Implication of TIGIT(+) human memory B cells in immune regulation
por: Hasan, Md Mahmudul, et al.
Publicado: (2021)

Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics
por: Rai, Ayushi, et al.
Publicado: (2021)

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)

Mechanisms of TIGIT-driven immune suppression in cancer
por: Kurtulus, Sema, et al.
Publicado: (2014)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

Theranostic applications of selenium nanomedicines against lung cancer
por: Liu, Shaowei, et al.
Publicado: (2023)

Recent Progress in the Theranostics Application of Nanomedicine in Lung Cancer
por: Mukherjee, Anubhab, et al.
Publicado: (2019)

TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance
por: Fu, Wenyan, et al.
Publicado: (2021)

TIGIT, a novel immune checkpoint therapy for melanoma
por: Tang, Wei, et al.
Publicado: (2023)

Functionalization of Metal and Carbon Nanoparticles with Potential in Cancer Theranostics
por: Mauro, Nicolò, et al.
Publicado: (2021)

Anti-TIGIT therapies for solid tumors: a systematic review
por: Rousseau, A., et al.
Publicado: (2023)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
por: Yeo, Jinah, et al.
Publicado: (2021)

Expression and Clinical Significance of TIGIT in Primary Breast Cancer
por: Tang, Limin, et al.
Publicado: (2023)

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer
por: Blessin, Niclas C., et al.
Publicado: (2019)

The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers
por: Freitas, Lucas F., et al.
Publicado: (2021)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

Current status of theranostics in prostate cancer
por: Virgolini, Irene, et al.
Publicado: (2017)

Theranostic Potential of Oncolytic Vaccinia Virus
por: Rojas, Juan J, et al.
Publicado: (2012)

Liposomes for Cancer Theranostics
por: Fernandes, Donald A.
Publicado: (2023)

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
por: Brazel, Danielle, et al.
Publicado: (2023)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

The influence of protein corona on Graphene Oxide: implications for biomedical theranostics
por: Quagliarini, Erica, et al.
Publicado: (2023)

Porphyrin Macrocycles: General Properties and Theranostic Potential
por: Boscencu, Rica, et al.
Publicado: (2023)

Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies
por: Shakil, Md Salman, et al.
Publicado: (2022)

Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
por: Pescia, Carlo, et al.
Publicado: (2023)

Managing hyponatremia in lung cancer: latest evidence and clinical implications
por: Fiordoliva, Ilaria, et al.
Publicado: (2017)

Copper-64: a real theranostic agent
por: Gutfilen, Bianca, et al.
Publicado: (2018)

Magnetic Nanoparticles in Cancer Theranostics
por: Gobbo, Oliviero L., et al.
Publicado: (2015)

Chemodynamic nanomaterials for cancer theranostics
por: Xin, Jingqi, et al.
Publicado: (2021)

Biological functions and theranostic potential of HMGB family members in human cancers
por: Niu, Liaoran, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p8krmhu1g2f1061onor8tc2pc4